Universal artificial antigen presenting cells to selectively propagate t cells expressing chimeric antigen receptor independent of specificity

Journal of Immunotherapy

Volumn 37, Issue 4, 2014, Pages 204-213

  Rushworth, David ^a   Jena, Bipulendu ^a   Olivares, Simon ^a   Maiti, Sourindra ^a   Briggs, Neima ^a   Somanchi, Srinivas ^a   Dai, Jianliang ^a,b   Lee, Dean ^a   Cooper, Laurence J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

AAPC (artificial antigen presenting cell); CAR (chimeric antigen receptor); Ex vivo propagation; Gene therapy; Manufacturing; Sleeping Beauty; T cell

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CHIMERIC ANTIGEN RECEPTOR LIGAND; IMMUNOGLOBULIN G4; LIGAND; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CD19 ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; ARTIFICIAL CELL; CELL EXPANSION; CELL STRAIN K 562; CHIMERA; COCULTURE; CONTROLLED STUDY; EX VIVO STUDY; FEEDER CELL; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; T CELL CULTURE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; K562 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD19; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; MICE; RECEPTORS, ANTIGEN; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84898009421     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000032     Document Type: Article

References (30)

1. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73, p1-11.
2. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimericantigen- receptor-transduced T cells. Blood. 2012;119: 2709-2720.
3. Huls MH, Figliola MJ, Dawson MJ, et al. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013;72:e50070.
4. Wang X, Naranjo A, Brown CE, et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother. 2012;35:689-701.
5. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32:169-180.
6. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32:689-702.
7. Chinnasamy N, Wargo JA, Yu Z, et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol. 2011;186:685-696.
8. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620-626.
9. Kung P, Goldstein G, Reinherz EL, et al. Monoclonal antibodies defining distinctive human T cell surface antigens. Science. 1979;206:347-349.
10. Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1:49-55.
11. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961-2971.
12. Puls R, Minchin R. Gene transfer and expression of a non-viral polycation-based vector in CD4+ cells. Gene Ther. 1999;6: 1774-1778.
13. Nakazawa Y, Huye LE, Dotti G, et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009;32:826-836.
14. Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255-1263.
15. Numbenjapon T, Serrano LM, Chang WC, et al. Antigenindependent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol. 2007; 35:1083-1090.
16. d'Azzo A, Tessitore A, Sano R. Gangliosides as apoptotic signals in ER stress response. Cell Death Differ. 2006;13: 404-414.
17. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood. 2003; 101:1637-1644.
18. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15:981-988.
19. Davies JK, Singh H, Huls H, et al. Combining CD19 redirection and alloanergization to generate tumor-specifichuman T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 2010;70:3915-3924.
20. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66: 10995-11004.
21. Alvarez-Rueda N, Desselle A, Cochonneau D, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PloS One. 2011;6:e25220.
22. Wang Z, Raifu M, Howard M, et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 30 to 50 exonuclease activity. J Immunol Methods. 2000;233:167-177.
23. Deniger DC, Switzer K, Mi T, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013;21:638-647.
24. Zhang M, Maiti S, Bernatchez C, et al. A new approach to simultaneously quantify both TCR alpha- and beta-chain diversity after adoptive immunotherapy. Clin Cancer Res. 2012;18:4733-4742.
25. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224.
26. Helfand SC, Hank JA, Gan J, et al. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Cell Immunol. 1996;167:99-107.
27. Duong CP, Westwood JA, Yong CS, et al. Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PloS One. 2013;8:e63037.
28. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19:3153-3164.
29. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165-1174.
30. Yvon E, Del Vecchio M, Savoldo B, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2- specific T cells. Clin Cancer Res. 2009;15:5852-5860.